Christina Yingxian Chen

Christina Yingxian Chen

Auto-generated profile, based on publicly available information

Christina Yingxian Chen

Department of Physiology, Pennsylvania Muscle Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2016 in Science
Verified
Journal Article
Closed access
PDF file
PRPatrick Robison
Patrick Robison
MCMatthew A. Caporizzo
Matthew A. Caporizzo
HAHossein Ahmadzadeh
Hossein Ahmadzadeh
ABAlexey I. Bogush
Alexey I. Bogush
CCChristina Yingxian Chen
Christina Yingxian Chen
BPBenjamin L. Prosser
Benjamin L. Prosser
A close-up view of cardiac cell mechanics: Heart cells contain a very well-organized array of cytoskeletal elements, including actin and microtubules that help them to perform their mechanical functions. Robison et al. used an advanced imaging approach to study the inner workings of mouse cardiac myocytes in real time. They observed microtubule “buckling” under contractile force in beating cardiomyocytes. This buckling was regulated by interaction with desmin and by the tubulin tyrosination state. The findings suggest a role for stable detyrosinated microtubules whose buckling under tension contributes to cardiac muscle strength. Science , this issue p. 10.1126/science.aaf0659

11 June 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
CCChristina Yingxian Chen
Christina Yingxian Chen
MCMatthew A. Caporizzo
Matthew A. Caporizzo
KBKenneth Bedi
Kenneth Bedi
AVAlexia Vite
Alexia Vite
ABAlexey I. Bogush
Alexey I. Bogush
BPBenjamin L. Prosser
Benjamin L. Prosser

9 August 2019 in Experimental Biology and Medicine
Verified
Journal Article
Open access
PDF file
MCMatthew A Caporizzo
Matthew A Caporizzo
CCChristina Yingxian Chen
Christina Yingxian Chen
BPBenjamin L Prosser
Benjamin L Prosser
Cardiomyocytes are large (∼40,000 µm3), rod-shaped muscle cells that provide the working force behind each heartbeat. These highly structured cells are packed with dense cytoskeletal networks that can be divided into two groups—the contractile (i.e. sarcomeric) cytoskeleton that consists of filamentous actin-myosin arrays organized into myofibrils, and the non-sarcomeric cytoskeleton, which is composed of β- and γ-actin, microtubules, and intermediate filaments. Together, microtubules and intermediate filaments form a cross-linked scaffold, and these networks are responsible for the delivery of intracellular cargo, the transmission of mechanical signals, the shaping of membrane systems, and the organization of myofibrils and organelles. Microtubules are extensively altered as part of both adaptive and pathological cardiac remodeling, which has diverse ramifications for the structure and function of the cardiomyocyte. In heart failure, the proliferation and post-translational modification of the microtubule network is linked to a number of maladaptive processes, including the mechanical impediment of cardiomyocyte contraction and relaxation. This raises the possibility that reversing microtubule alterations could improve cardiac performance, yet therapeutic efforts will strongly benefit from a deeper understanding of basic microtubule biology in the heart. The aim of this review is to summarize the known physiological roles of the cardiomyocyte microtubule network, the consequences of its pathological remodeling, and to highlight the open and intriguing questions regarding cardiac microtubules.Impact statement: Advancements in cell biological and biophysical approaches and super-resolution imaging have greatly broadened our view of tubulin biology over the last decade. In the heart, microtubules and microtubule-based transport help to organize and maintain key structures within the cardiomyocyte, including the sarcomere, intercalated disc, protein clearance machinery and transverse-tubule and sarcoplasmic reticulum membranes. It has become increasingly clear that post translational regulation of microtubules is a key determinant of their sub-cellular functionality. Alterations in microtubule network density, stability, and post-translational modifications are hallmarks of pathological cardiac remodeling, and modified microtubules can directly impede cardiomyocyte contractile function in various forms of heart disease. This review summarizes the functional roles and multi-leveled regulation of the cardiac microtubule cytoskeleton and highlights how refined experimental techniques are shedding mechanistic clarity on the regionally specified roles of microtubules in cardiac physiology and pathophysiology.

3 November 2021 in Science Translational Medicine
Verified
Journal Article
Closed access
QMQuentin McAfee
Quentin McAfee
CCChristina Yingxian Chen
Christina Yingxian Chen
YYYifan Yang
Yifan Yang
MCMatthew A. Caporizzo
Matthew A. Caporizzo
MMMichael Morley
Michael Morley
ZAZolt Arany
Zolt Arany
Truncating mutations in TTN result in both truncated titin proteins and reduced full-length titin in patient hearts.

25 July 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
KCKevin K. Chiou
Kevin K. Chiou
JRJason W. Rocks
Jason W. Rocks
CCChristina Yingxian Chen
Christina Yingxian Chen
SCSangkyun Cho
Sangkyun Cho
KMKoen E. Merkus
Koen E. Merkus
ALAndrea J. Liu
Andrea J. Liu
Significance: There is a mounting body of evidence that physical forces induce biochemical changes. Here, we suggest that the early embryonic heart provides a striking illustration of the importance of mechanics in living matter. Whereas adult hearts use electrical signaling to coordinate the heartbeat, we propose that embryonic hearts use mechanical signaling. We model the embryonic heart as mechanically excitable tissue, with cardiac myocytes that are triggered to contract under strain. Such contractions exert strains on nearby cells and induce further contraction, thus propagating the signal through the heart. This simple model captures key features observed in the heartbeat of stiffness-modified embryonic hearts that cannot be explained by standard electrochemical signaling and yields predictions that we confirm with experiments.

10 April 2020 in Circulation Research
Verified
Journal Article
Closed access
PDF file
CCChristina Yingxian Chen
Christina Yingxian Chen
ASAlexander K. Salomon
Alexander K. Salomon
MCMatthew Alexander Caporizzo
Matthew Alexander Caporizzo
SCSam Curry
Sam Curry
NKNeil A. Kelly
Neil A. Kelly
BPBenjamin L. Prosser
Benjamin L. Prosser
Rationale: Impaired myocardial relaxation is an intractable feature of several heart failure (HF) causes. In human HF, detyrosinated microtubules stiffen cardiomyocytes and impair relaxation. Yet the identity of detyrosinating enzymes have remained ambiguous, hindering mechanistic study and therapeutic development. Objective: We aimed to determine if the recently identified complex of VASH1/2 (vasohibin 1/2) and SVBP (small vasohibin binding protein) is an active detyrosinase in cardiomyocytes and if genetic inhibition of VASH-SVBP is sufficient to lower stiffness and improve contractility in HF. Methods and Results: Transcriptional profiling revealed that VASH1 transcript is >10-fold more abundant than VASH2 in human hearts. Using short hairpin RNAs (shRNAs) against VASH1 , VASH2 , and SVBP , we showed that both VASH1- and VASH2-SVBP complexes function as tubulin carboxypeptidases in cardiomyocytes, with a predominant role for VASH1. We also generated a catalytically dead version of the tyrosinating enzyme TTL (TTL-E331Q) to separate the microtubule depolymerizing effects of TTL from its enzymatic activity. Assays of microtubule stability revealed that both TTL and TTL-E331Q depolymerize microtubules, while VASH1 and SVBP depletion reduce detyrosination independent of depolymerization. We next probed effects on human cardiomyocyte contractility. Contractile kinetics were slowed in HF, with dramatically slowed relaxation in cardiomyocytes from patients with HF with preserved ejection fraction. Knockdown of VASH1 conferred subtle kinetic improvements in nonfailing cardiomyocytes, while markedly improving kinetics in failing cardiomyocytes. Further, TTL, but not TTL-E331Q, robustly sped relaxation. Simultaneous measurements of calcium transients and contractility demonstrated that VASH1 depletion speeds kinetics independent from alterations to calcium cycling. Finally, atomic force microscopy confirmed that VASH1 depletion reduces the stiffness of failing human cardiomyocytes. Conclusions: VASH-SVBP complexes are active tubulin carboxypeptidases in cardiomyocytes. Inhibition of VASH1 or activation of TTL is sufficient to lower stiffness and speed relaxation in cardiomyocytes from patients with HF, supporting further pursuit of detyrosination as a therapeutic target for diastolic dysfunction.